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ABSTRACT
Objective To assess whether younger, but not older,
women in China have higher in-hospital mortality
following ST-Segment Elevation Myocardial Infarction
(STEMI) compared with men, and whether this
relationship varied over the last decade or across
rural/urban areas.
Methods We analysed a nationally representative
sample of 11 986 patients with STEMI from 162
Chinese hospitals in 2001, 2006 and 2011, in the
China PEACE-Retrospective AMI Study and compared
in-hospital mortality between women and men with
gender–age interactions in multivariable models.
Results The overall in-hospital mortality rate was
higher in women compared with men (17.2% vs 9.1%,
p<0.0001; unadjusted OR 2.07, 95% CI 1.85 to 2.33).
The unadjusted OR for mortality in women, compared
with men, was 2.20 (95% CI 1.59 to 3.04), 2.21 (95%
CI 1.74 to 2.79), 1.37 (95% CI 1.15 to 1.65) and 1.25
(95% CI 0.97 to 1.63) for ages <60, 60–69, 70–79
and ≥80 years, respectively. After adjustment for patient
characteristics, hospital characteristics and year of study,
the OR for mortality comparing women with men was
1.69 (95% CI 1.01 to 2.83), 1.64 (95% CI 1.24 to
2.19), 1.15 (95% CI 0.90 to 1.46) and 0.82 (95% CI
0.60 to 1.11) for ages <60, 60–69, 70–79 and
≥80 years, respectively. The gender–age interaction for
mortality was statistically signiﬁcant (p=0.009), even
after adjustment for a wide range of confounders, and
did not vary over time or across rural/urban areas.
Conclusions Among a Chinese population with STEMI,
gender differences in early mortality were age-dependent
and greatest in the younger groups <70 years of age.
Trial registration number http://www.clinicaltrials.
gov (NCT01624883).
INTRODUCTION
Several studies from high-income areas, including
the USA, Canada and Europe, have demonstrated
gender differences in mortality following acute
myocardial infarction (AMI) that vary by age,1–8
with a higher risk of death in younger women com-
pared with their male counterparts. For example,
in a US study of patients hospitalised with AMI
between 1994 and 1998, women aged ≤50 years
had a more than twofold greater in-hospital mortal-
ity compared with similarly aged men,2 but this dif-
ference was not present in older patients. A
remaining question is whether this gender–age
interaction in AMI mortality, in which gender dif-
ferences are greater in younger patients, exists in
diverse populations and healthcare systems, espe-
cially in low-income and middle-income countries.
In China, home to one-ﬁfth of the world’s
women, there is a rising burden of cardiovascular
disease.9 Moreover, as observed in the recently pub-
lished China Patient-centered Evaluative Assessment
of Cardiac Events (China PEACE)- Retrospective
AMI Study of patients with ST-Segment Elevation
Myocardial Infarction (STEMI), there was a four-
fold increase in hospital admissions among both
men and women over the last decade, with women
persistently accounting for nearly 30% of all
patients.10 In this growing population of women
with AMI, it is critical to understand whether
gender differences in survival among different age
groups exist, especially as China prepares to
embark on national efforts to improve the quality of
AMI care.
Examining potential gender disparities in STEMI
outcomes in China is important, as ﬁndings from
Western countries may not be broadly applicable.
Though prior studies from China have suggested
higher rates of death in younger women after
STEMI,11 these data are not contemporary and
may not reﬂect the experience of average patients
as they were based on clinical trial populations.
Further investigation is needed to understand
whether age–gender disparities exist among a
nationally representative sample and whether dif-
ferences in outcomes have changed over the last
decade. Additionally, to inform future interven-
tions, it is important to understand whether any
differences observed can be explained by patient
risk, hospital care management or the settings in
which care is delivered.
Accordingly, we examined a nationally represen-
tative sample of patients with STEMI in the China
PEACE-Retrospective AMI Study in 2001, 2006
and 2011. The objectives of this study were to (a)
assess whether there is a signiﬁcant gender–age
interaction with in-hospital mortality among
Chinese patients with STEMI; (b) identify factors
that may explain this gender–age interaction and
(c) determine whether this gender–age interaction
has changed over time or varies across rural/urban
areas. We hypothesised that younger, but not older,
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women with STEMI in China would have a higher risk of
in-hospital mortality, compared with age-matched men. The
ﬁndings of this study will assist in identifying vulnerable groups
at risk for early mortality, identifying potential mediators of
mortality differences, and stimulating quality improvement
efforts to improve outcomes for younger women with STEMI.
METHODS
Data source and study population
The design of the China PEACE-Retrospective AMI Study has
been previously described.12 In brief, we created a nationally
representative sample of hospitalisations for AMI during 2001,
2006 and 2011 using a 2-stage random sampling design. Since
hospital volumes and clinical capacities differ between urban
and rural areas, as well as among the 3 ofﬁcial economic–geo-
graphic regions of China, we identiﬁed hospitals in 5 strata:
Eastern-rural, Central-rural, Western-rural, Eastern-urban and
Central/Western-urban regions. We then used systematic random
sampling to sample cases with AMI, which were identiﬁed using
International Classiﬁcation of Diseases versions 9 and 10, when
available, or through principle discharge diagnosis terms from
the selected hospitals.
We included patients with STEMI (n=13 815), which was
conﬁrmed by discharge diagnosis and electrocardiogram results.
For the purposes of the present analysis, patients who were
transferred in (n=559), transferred out (n=1148) or discharged
within 24 h of admission (n=122) were excluded. The ﬁnal
study cohort consisted of 11 986 patients (n=3574 women,
29.8%).
The Chinese government, which provided ﬁnancial support
for the study, had no role in the design or conduct of the study;
in the collection, management, analysis and interpretation of
the data; or in the preparation or approval of the manuscript.
The central ethics committee of the China National Center for
Cardiovascular Diseases approved this study. All collaborating
hospitals accepted the central ethics approval except for 5 hospi-
tals that obtained local approval by internal ethics committees.
The study is registered at http://www.clinicaltrials.gov
(NCT01624883).
Medical record review and variables
Data were collected via standardised central medical chart
abstraction using standardised data deﬁnitions. Variables
abstracted from the medical records of each hospital included
patient-level characteristics, hospital-level characteristics, year of
discharge, length of stay, and in-hospital outcomes. In-hospital
mortality was deﬁned as a composite of death during hospital-
isation or withdrawal from treatment due to a terminal status at
discharge. Withdrawal from treatment is common in China due
to many patients’/families’ reluctance to die in the hospital. The
Chinese government uses in-hospital death or withdrawal from
treatment as an indicator of quality for hospitals.13 14
Composite complications included re-infarction, cardiogenic
shock, cardiac arrest, congestive heart failure, and ischaemic
stroke (for deﬁnitions, see online supplementary appendix).
Major bleeding included any intracranial bleeding; or absolute
drop of haemoglobin of at least 5 g/dL; or bleeding resulting in
hypovolemic shock or fatal bleeding (bleeding that directly
results in death within 7 days).
Statistical analysis
Based on the distribution of in-hospital mortality among
women and men, as well as the cut-off of age used in a previous
landmark manuscript,2 we stratiﬁed the study sample into 4
pre-speciﬁed age groups (<60, 60–69, 70–79, and ≥80 years).
Continuous variables were expressed as mean±SD and com-
pared using unpaired t test. Using χ2 tests, we compared cardio-
vascular risk factors, medical history, clinical characteristics at
admission, treatment during hospitalisation, in-hospital out-
comes, hospital characteristics, and year of discharge between
women and men in each age group. Crude ORs with 95% CIs
for women versus men were reported.
We used multivariable logistic regression models to calculate
adjusted OR and 95% CI for in-hospital mortality in the overall
population and within each age group, and to determine
whether there was a signiﬁcant interaction between gender and
age with respect to in-hospital mortality. Candidate variables for
inclusion in the multivariable models included cardiovascular
risk factors, medical history, clinical characteristics at admission,
treatment during hospitalisation, length of stay, hospital
characteristics, and year of discharge. The ﬁnal models included
only those variables that differed signiﬁcantly between women
and men (p<0.05). We also assessed 2 three-way interaction
terms: (1) gender×age×year and (2) gender×age×rural/urban
to assess whether age-dependent gender differences in
in-hospital mortality changed either (a) over time or (b) across
rural/urban areas. All comparisons were 2-tailed, with a p
value<0.05 considered statistically signiﬁcant. Statistical analyses
were performed using SAS software (V.9.2, SAS Institute, Cary,
North Carolina, USA) and R software (V.3.0.2).
RESULTS
Baseline characteristics
Women presenting with STEMI were signiﬁcantly older than
men with STEMI (69.8±10.4 years vs 62.6±12.6 years,
respectively, p<0.001). Younger women (<60 years) were more
likely to have hypertension (OR=1.84; 95% CI 1.54 to 2.20),
diabetes (OR=2.06; 95% CI 1.68 to 2.54) and were less likely
to smoke (OR=0.09; 95% CI 0.07 to 0.12) compared with
men. Women over the age of 60 years were also less likely to
have had a prior AMI. Differences in these cardiovascular risk
factors were attenuated in the older age groups (table 1).
Clinical characteristics at presentation also differed between
women and men with signiﬁcant variations by age group.
Younger women (<60 years) were more likely than similarly
aged men to have symptoms lasting >24 h before hospital
admission, while older women (aged 60–69 and 70–79 years)
were less likely to have experienced chest discomfort compared
with men. Younger women (<60 years) had higher systolic
blood pressures and higher heart rates (≥100 bpm), but fewer
cardiac arrests at presentation compared with similarly aged
men and with older women. Additionally, younger women had
worse renal function (glomerular ﬁltration rate <60 mL/min)
and higher low-density lipoprotein cholesterol levels than their
male peers at presentation. Of note, women <60 years of age
were more likely to live in rural than in urban areas (table 1).
In-hospital treatments also varied by gender and age.
Younger women (<60 years) were less likely to receive clopido-
grel within 24 h of admission (OR=0.80; 95% CI 0.67 to
0.95) or any statin therapy during hospitalisation (OR=0.79;
95% CI 0.65 to 0.96). Women aged 60–69 years were also less
likely to receive aspirin, clopidogrel and β-blockers within 24 h
of admission and statins during hospitalisation. With respect to
reperfusion strategies, women aged <80 years were less likely
to receive any reperfusion, especially those <60 years
(OR=0.68; 95% CI 0.56 to 0.81), including less primary per-
cutaneous coronary intervention (PCI) within 24 h (OR=0.54;
95% CI 0.40 to 0.73), compared with similarly aged men. All
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women were less likely to undergo cardiac catheterisation and
those 60–69 and 70–79 years of age were less likely to
undergo PCI or any revascularisation compared with their
male peers (table 2).
Finally, women <60 years of age had higher rates of any com-
posite complications than men, while there were no signiﬁcant
gender differences among other age groups. The rate of major
bleeding was similar by gender in each age group (table 2).
Table 1 Unadjusted OR for characteristics of patients and hospitals comparing women with men according to age












Hypertension 56.4 45.5 1.84† 1.43† 1.37† 1.13
Diabetes 25.6 16.3 2.06† 1.98† 1.68† 1.27
Current smoker 10.1 44.5 0.09† 0.16† 0.26† 0.26†
Medical history
MI 9.2 10.8 0.87 0.72† 0.80† 0.50†
PCI 1.2 1.8 0.64 0.58 0.85 0.16†
Stroke 12.7 10.8 1.26 1.02 0.93 1.00
Clinical characteristics at admission
Symptom onset to presentation (h)
≤12 46.8 51.3 0.70† 0.95 0.91 1.18
>12 to ≤24 14.5 12.1 1.18 1.18 1.21 1.01
>24 38.8 36.6 1.36† 0.97 1.00 0.84
Chest discomfort 89.7 93.3 0.81 0.66† 0.77† 0.93
SBP (mm Hg)
≥140 39.2 32.1 1.57† 1.22† 1.27† 1.29†
90–139 54.0 62.4 0.66† 0.81† 0.78† 0.69†
<90 6.8 5.6 0.91 1.09 1.06 1.62†
HR (bpm)
≥100 19.7 13.2 1.68† 1.47† 1.44† 1.29
Anterior AMI 23.9 23.6 0.95 0.94 1.06 1.22
Cardiac arrest 0.9 1.4 0.33† 0.86 1.53 0.86
Cardiogenic shock 7.5 5.4 1.15 1.33 1.25 1.22
eGFR (mL/min/1.73 m2)
≥90 23.6 35.0 0.68† 0.75† 0.90 0.92
≥60–<90 31.2 32.5 1.19 0.81† 0.83† 0.76†
<60 28.6 16.9 2.08† 1.61† 1.26† 1.23†
Unmeasured 16.6 15.7 0.99 1.24† 1.09 1.20
LDL-C (mg/dL)
<100 27.7 34.9 0.77† 0.55† 0.66† 0.73†
≥100 to <130 23.8 24.1 1.00 1.04 1.04 1.15
≥130 19.6 16.2 1.08 1.37† 1.62† 1.52†
Unknown 29.0 24.9 1.23† 1.44† 1.09 1.00
Hospital characteristics
Economic–geographic region
Eastern 62.4 57.6 1.24† 1.35† 1.16† 0.96
Central 20.0 22.0 0.80† 0.80† 0.99 1.10
Western 17.6 20.5 0.92 0.79† 0.80† 0.95
Rural/Urban
Rural 40.3 37.4 1.29† 0.98 0.98 1.09
Urban 59.7 62.6 0.78† 1.02 1.02 0.92
PCI-capable hospital 58.7 61.0 0.88 0.93 0.99 0.93
Hospital with CCU 78.2 78.8 0.85 1.00 1.07 1.10
Teaching hospital 79.2 81.1 0.90 0.75† 1.00 0.89
Year of discharge
2001 15.9 16.2 1.11 1.20† 0.91 0.74
2006 29.1 30.2 0.94 0.93 0.95 0.88
2011 55.0 53.6 0.99 0.94 1.10 1.26†
*The OR is for the comparison of women with men.
†The OR is significant between women and men.
CCU, coronary care unit; eGFR, estimated glomerular filtration rate; HR, heart rate; LDL-C, low-density lipoprotein cholesterol; MI: myocardial infarction; PCI, percutaneous coronary
intervention; SBP, systolic blood pressure.
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Unadjusted in-hospital mortality
The overall in-hospital mortality rate was higher in women than
in men (17.2% vs 9.1%, p<0.0001; unadjusted OR 2.07, 95%
CI 1.85 to 2.33). In-hospital mortality following STEMI
increased with age for both genders. Among younger women
(<60 years), the in-hospital mortality rate was twofold higher
compared with men (9.4% vs 4.5%, p<0.0001; unadjusted
OR=2.20, 95% CI 1.59 to 3.04), and similarly for women
aged 60–69 years (15.2% vs 7.5%, p<0.0001; unadjusted
OR=2.21, 95% CI 1.74 to 2.79). A higher risk of death was
also observed among older women 70–79 years of age (18.6%
vs 14.3%, p=0.0006; unadjusted OR=1.37, 95% CI 1.15 to
1.65), but there was no difference in the risk of death in women
over 80 years of age (24.8% vs 20.8%, p=0.09; unadjusted
OR=1.25, 95% CI 0.97 to 1.63). When mortality rates were
examined by age, a gender–age interaction was observed
(p=0.0007) (ﬁgure 1). In addition, we also found that women
aged 60–69, as well as ≥80 years of age, were more likely to
die within 24 h of admission compared with their male peers
(table 2).
The gender–age–year interaction was not signiﬁcant
(p=0.38), indicating that the gender–age interaction did not
change over time (ﬁgure 2). In addition, there was no gender–
age–area (rural/urban) interaction (p=0.95), suggesting equally
poor outcomes in women regardless of whether they were
treated in urban or in rural hospitals.
Table 2 Unadjusted OR for treatments, testing and in-hospital outcomes comparing women with men according to age












Aspirin≤24 h 83.9 87.5 0.83 0.75† 0.90 0.90
Clopidogrel≤24 h 51.5 56.6 0.80† 0.81† 0.86† 1.01
β-Blocker≤24 h 43.8 48.5 0.87 0.84† 1.06 0.98
ACE-I/ARB‡ 60.2 63.8 0.90 0.88 0.90 0.73†
Statin‡ 73.0 75.2 0.79† 0.85† 1.02 1.02
Reperfusion therapies ≤24 h
Primary PCI 8.5 12.8 0.54† 0.85 0.81 0.76
Fibrinolytic therapy 18.9 24.7 0.88 0.88 0.87 1.00
Any reperfusion 27.4 37.5 0.68† 0.84† 0.82† 0.86
Staged procedures
Cardiac catheterisation 18.8 28.8 0.72† 0.68† 0.71† 0.64†
PCI 8.6 13.9 0.84 0.67† 0.66† 0.59
CABG 0.34 0.61 0.58 0.41 1.02 –
Any revascularisation 8.9 14.4 0.84 0.64† 0.67† 0.59
Testing
Troponin 48.9 49.9 0.85 0.90 0.96 1.06
Echocardiogram 46.1 52.6 0.97 0.67† 0.90 0.93
In-hospital outcomes
Death‡ 12.5 6.7 2.29† 2.21† 1.20 1.38
Death‡ + withdrawal from treatment 17.2 9.1 2.20† 2.21† 1.37† 1.25
Death within 24h 5.5 2.9 1.75 2.21† 1.34 1.89†
Composite complications 15.3 11.8 1.46† 1.21 1.17 1.29
Major bleeding 0.8 1.0 0.22 0.74 1.07 0.44
Length of stay (days)
<8 29.5 22.7 1.03 0.73† 1.07 1.21†
8–11 20.9 24.0 1.35† 0.87 0.89 0.96
12–15 21.4 23.4 1.22† 1.06 0.87 0.88
≥16 28.2 29.8 1.60† 0.83 1.07 0.62†
*The OR is for the comparison of women with men.
†The OR is significant between women and men.
‡During hospitalisation.
ACE-I/ARB, angiotensin converting enzyme inhibitor/angiotensin receptor blocker; Composite complication: recurrent MI, cardiac shock, cardiac arrest, congestive heart failure and
ischaemic stroke; CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention.
Figure 1 In-hospital mortality rate following ST-segment elevation
myocardial infarction among women and men by age. The interaction
between gender and age was statistically signiﬁcant (p=0.0007).
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Multivariable-adjusted in-hospital mortality
In the multivariable model, even after adjustment for differences
in patient characteristics, hospital characteristics, length of stay and
year of discharge, the interaction between gender and age for
in-hospital mortality remained signiﬁcant (p=0.0012). The
adjusted OR for in-hospital mortality, comparing women with
men, was 1.69 (95% CI 1.01 to 2.83), 1.64 (95% CI 1.24 to
2.19), 1.15 (95% CI 0.90 to 1.46) and 0.82 (95% CI 0.60 to
1.11) for age <60 years, age 60–69, age 70–79 and age ≥80 years,
respectively. Women <70 years of age had an excess risk of mor-
tality as compared with men; while there was no signiﬁcant gender
difference among patients ≥70 years old (ﬁgure 3).
DISCUSSION
In this ﬁrst study to investigate gender differences in in-hospital
mortality across the spectrum of age in a nationally representa-
tive population of patients with STEMI in China, women
younger than 70 years had a >60% increased odds of dying in
the hospital, compared with similarly aged men. This pattern of
mortality was observed after accounting for differences in a
wide range of patient and hospital characteristics. These mortal-
ity differences persisted despite changes in cardiovascular epi-
demiology over the last decade and differences in healthcare
resources across rural and urban settings.
Our ﬁndings extend the previous literature, primarily based
on US patients, by showing signiﬁcant gender differences in out-
comes by age in China, a low-income and middle-income
country with a large, potentially very different patient popula-
tion and with different challenges and inequalities in healthcare
services than more highly resourced Western countries.3 5 15
Some differences between the USA and China do exist,
however, in the USA, there was a twofold higher risk of death in
the sub-group of women aged <50 years,15 while in the current
study of Chinese patients the increased risk of death was
observed among older patients as well, up to 70 years of age.
The reasons for this international difference are unknown and
worthy of further investigation. Based on the current data, and
on our knowledge of gender differences in coronary heart
Figure 2 Unadjusted risk of in-hospital mortality comparing women with men according to age (2001, 2006 and 2011). The interaction among
gender, age and year was not statistically signiﬁcant (p=0.38).
Figure 3 Unadjusted and adjusted risk of in-hospital mortality comparing women with men by age. In the unadjusted data (left panel), the
interaction between gender and age was statistically signiﬁcant (p=0.0009). After adjustment for differences in patient characteristics, hospital
characteristics and year of discharge (right panel), the interaction between gender and age remained statistically signiﬁcant (p=0.0012).
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disease, there are several potential explanations for the higher
risk of mortality in younger women compared with similarly
aged men.
Cardiovascular risk factors and co-morbidities have been con-
sidered as important contributors to gender-related mortality
differences in younger patients.1 3 16 We speculated that, in our
study, a higher burden of cardiovascular risk, such as diabetes,
hypertension and chronic renal insufﬁciency, in younger women
could contribute to the higher risk in mortality in this group.
Women who develop atherosclerosis at a young age or in
middle age may represent a distinct phenotype, whereby cardio-
vascular risk factors outweigh the protective effects of oestrogen
and portend a higher risk of premature cardiovascular events
and adverse outcomes following these events.1 In addition to
considering the higher prevalence of these risk factors in
younger women than their male peers, as well as their associ-
ation with prognosis after AMI,17–19 moreover, in the
INTERHEART study, such risk factors as diabetes and hyperten-
sion were more strongly associated with the development of
myocardial infarction in women than in men, as well as in
younger women (<60 years) compared with older (≥60 years)
women.20 As such, several strategies, including prevention and
the early identiﬁcation and aggressive management of risk
factors before the event, may be a target for future efforts to
reduce the excess risk of mortality following STEMI among
younger women, especially in China, a developing country with
rapidly increasing cardiovascular risk factor burdens.21–24
Other possible explanations for the poor prognosis observed
among younger women include a lack of awareness of symp-
toms, under-recognition at presentation and lower application
of evidence-based medication and timely reperfusion therapy. In
our study, women aged <60 years had a longer time from
symptom onset to admission compared with other age groups,
which may explain the less frequent use of early reperfusion
and, ultimately, the higher risk of mortality in this age group.
Delayed hospital presentation in younger women may be due to
atypical symptom onset of AMI,25 which can also result in
delayed detection of the condition after the patients arrive at
hospital.26 In addition, less use of evidence-based therapies at
admission may contribute to the higher mortality in younger
women. Of note, the US studies have found that the gender dif-
ference in evidence-based treatment did not adequately account
for the observed mortality disparity.2 27 However, in developing
countries, addressing the aforementioned disparities in disease
awareness,28 recognition and timely administration of evidence-
based therapies could lead to meaningful improvements in the
care of young women with AMI and should be a target of
future interventions.
In our study, however, adjustment for differences in
co-morbidities, clinical characteristics at admission, treatments,
and hospital characteristics did not eliminate the gender–age
interaction, suggesting the contribution of alternative mechan-
isms to this observation. Other clinical factors not measured in
this study, such as door-to-balloon time and coronary angio-
graphic characteristics, may be involved. Moreover, biological
factors not typically measured, including plaque type, clotting
mechanisms, coagulability states, hormonal status, and coron-
ary spasm, may also be involved. Alternatively, in the speciﬁc
context of China, the inﬂuence of socioeconomic, cultural,
educational and psychological factors29 30 differentially affect-
ing young women compared with men may be potential contri-
butors, especially in rural areas. Investigation into these and
other factors may have important implications for how we
educate patients and physicians, as well as how we assess
the risk and evaluate treatment strategies for younger women
with AMI.
Limitations
Our ﬁndings should be interpreted within the context of several
potential limitations. First, we lacked data on some important
clinical variables, such as door-to-balloon time, coronary angio-
graphic characteristics and other potential unmeasured factors,
which may have inﬂuenced management. However, we were
able to adjust for several potential confounders, including car-
diovascular risk, severity of illness on presentation and practice
management. Second, based on the random sampling design, we
may have had inadequate sample size to detect important differ-
ences within speciﬁc age groups. For example, the proportion of
premenopausal women was relatively low, which prevented us
from having an adequate sample size to investigate patients
<55 years of age. Finally, we had no information on pre-
hospital death and long-term health outcomes of patients with
STEMI.
CONCLUSIONS
Similar to ﬁndings in the USA and other developed countries,
among a Chinese population with STEMI, gender differences in
early mortality were age-dependent and greatest among the
younger groups <70 years of age. This pattern persisted even
after adjusting for a wide range of confounders, including
patient characteristics and hospital characteristics. Further
research is required to enhance the understanding and develop-
ment of interventions to improve the outcomes of younger
women, especially in low-income and middle-income countries
undergoing epidemiological transition like China.
Key messages
What is already known on this subject?
In studies from high-income areas such as the USA, Canada and
Europe, gender differences in mortality following acute
myocardial infarction (AMI) vary by age, with a higher risk of
death observed in younger women compared with their male
counterparts.
What might this study add?
In China, a low-income and middle-income country with a
diverse population and healthcare system, we also observed
signiﬁcantly higher in-hospital mortality among younger women
compared with men, following hospitalisation for ST-Segment
Elevation Myocardial Infarction (STEMI). This pattern persisted
after adjusting for a wide range of confounders, including
patient- and hospital-level characteristics, and did not vary over
time or across rural/urban areas. The gender differences were
greatest in the younger groups <70 years of age.
How might this impact on clinical practice?
These ﬁndings indicate that the higher risk of death among
younger women following AMI is a global health problem,
found in high-income countries and in developing nations such
as China. The ﬁndings identify young women as a vulnerable
group for in-hospital mortality after STEMI and underscore the
need for interventions to address this disparity.
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